Nestlé Skin Health

nestleskinhealth.com

Nestlé Skin Health’s mission is to enhance people's quality of life and contribute to a healthier future through science-based solutions for skin health, leading to our vision - to change the way the world thinks about skin health. As one of the category’s leading companies, Nestlé Skin Health conducts ground-breaking product research to provide both the healthcare community and the consumer with an ongoing progression of innovative technologies and products to protect, serve and enhance skin health.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

MATRIC TO ESTABLISH FIRST AND ONLY NATIONAL CENTER OF EXCELLENCE FOR PHARMACEUTICAL PROCESS DESIGN

The Mid-Atlantic Technology, | March 03, 2022

news image

The Mid-Atlantic Technology, Research & Innovation Center announced it will establish the Center of Excellence for process design, defining a new standardized process development framework to streamline chemical manufacturing processes from laboratory bench through to commercial production. The initial projects will develop continuous processes for critical materials for the pharmaceutical industry currently substantially produced overseas. These new capabilities will be established as a res...

Read More

Views and Analysis

CHMP RECOMMENDS APPROVAL OF DUPIXENT® (DUPILUMAB) FOR CHILDREN AGED 6 TO 11 YEARS WITH SEVERE ASTHMA WITH TYPE 2 INFLAMMATION

Regeneron Pharmaceuticals, Inc | January 31, 2022

news image

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending to extend the approval of Dupixent® (dupilumab) in the European Union (EU) to include add-on maintenance treatment for children aged 6 to 11 years with severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO) who are inadequate...

Read More

Business Insights

KYOWA KIRIN EXPANDS LICENSE AGREEMENT WITH SYNAFFIX AND TAKES EXCLUSIVE TARGET RIGHTS BASED ON LATEST POSITIVE ADC DATA

Synaffix | July 01, 2022

news image

Synaffix B.V. a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates with best-in-class therapeutic index, today announces that Kyowa Kirin Co., Ltd.a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, has expanded the license agreement with Synaffix by adding a third ADC target to its research evaluation and development effor...

Read More

Pharmacy Market

PCI PHARMA SERVICES ANNOUNCES THE CLOSING OF ITS ACQUISITION OF LSNE

PCI Pharma Services | December 15, 2021

news image

PCI Pharma Services a leading global contract development and manufacturing organizatio announced the closing of the previously announced acquisition of Lyophilization Services of New England, Inc. a premier contract development and manufacturing organization headquartered in Bedford, New Hampshire. This acquisition is a key step for PCI, as LSNE will expand PCI’s breadth of services as a global CDMO, building on its expertise in specialty manufacturing, clinical trial suppl...

Read More
news image

Business Insights

MATRIC TO ESTABLISH FIRST AND ONLY NATIONAL CENTER OF EXCELLENCE FOR PHARMACEUTICAL PROCESS DESIGN

The Mid-Atlantic Technology, | March 03, 2022

The Mid-Atlantic Technology, Research & Innovation Center announced it will establish the Center of Excellence for process design, defining a new standardized process development framework to streamline chemical manufacturing processes from laboratory bench through to commercial production. The initial projects will develop continuous processes for critical materials for the pharmaceutical industry currently substantially produced overseas. These new capabilities will be established as a res...

Read More
news image

Views and Analysis

CHMP RECOMMENDS APPROVAL OF DUPIXENT® (DUPILUMAB) FOR CHILDREN AGED 6 TO 11 YEARS WITH SEVERE ASTHMA WITH TYPE 2 INFLAMMATION

Regeneron Pharmaceuticals, Inc | January 31, 2022

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending to extend the approval of Dupixent® (dupilumab) in the European Union (EU) to include add-on maintenance treatment for children aged 6 to 11 years with severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO) who are inadequate...

Read More
news image

Business Insights

KYOWA KIRIN EXPANDS LICENSE AGREEMENT WITH SYNAFFIX AND TAKES EXCLUSIVE TARGET RIGHTS BASED ON LATEST POSITIVE ADC DATA

Synaffix | July 01, 2022

Synaffix B.V. a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates with best-in-class therapeutic index, today announces that Kyowa Kirin Co., Ltd.a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, has expanded the license agreement with Synaffix by adding a third ADC target to its research evaluation and development effor...

Read More
news image

Pharmacy Market

PCI PHARMA SERVICES ANNOUNCES THE CLOSING OF ITS ACQUISITION OF LSNE

PCI Pharma Services | December 15, 2021

PCI Pharma Services a leading global contract development and manufacturing organizatio announced the closing of the previously announced acquisition of Lyophilization Services of New England, Inc. a premier contract development and manufacturing organization headquartered in Bedford, New Hampshire. This acquisition is a key step for PCI, as LSNE will expand PCI’s breadth of services as a global CDMO, building on its expertise in specialty manufacturing, clinical trial suppl...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us